RE: All about Q323 Jul 2018 08:04
I think you are wrong... imo - the company have stated q3 2018. Yes there is some results in 2019 but this is due "shortly":
In respect of NXP002, our Strategic Review combined with emerging pre-clinical data strongly supports primary development towards a treatment for Idiopathic Pulmonary Fibrosis ("IPF"). The Company expects to announce completion of its pre-clinical IPF programme shortly, following initial positive pilot study results as previously announced. Our clinical partners have now received tissue from all required donors to complete the study, with anticipated reporting of results in Q3 2018. Formulation development is on-going as the Company positions itself for an initial patient proof-of-concept study in IPF prior to commercial out-licensing. Additional development opportunities and further partnerships are being explored in parallel.